Tralokinumab Provides Clinically Meaningful Responses at Week 16 in Adults with Moderate-to-Severe Atopic Dermatitis Who Do Not Achieve IGA 0/1

Eric L. Simpson, Andrew Blauvelt, Jonathan I. Silverberg, Michael J. Cork, Norito Katoh, Thomas Mark, Shannon K.R. Schneider, Andreas Wollenberg

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Tralokinumab Provides Clinically Meaningful Responses at Week 16 in Adults with Moderate-to-Severe Atopic Dermatitis Who Do Not Achieve IGA 0/1'. Together they form a unique fingerprint.

Medicine & Life Sciences